Amneal Pharmaceuticals, Inc. AMRX Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 9, 2023, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s other non-current liabilities?
- Amneal Pharmaceuticals, Inc. (AMRX) reported other non-current liabilities of $41.46M in Q1 2023.
- How has Amneal Pharmaceuticals, Inc.'s other non-current liabilities changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s other non-current liabilities increased by 26.1% year-over-year, from $32.87M to $41.46M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s other non-current liabilities?
- Over 2 years (2020 to 2022), Amneal Pharmaceuticals, Inc.'s other non-current liabilities has grown at a 2.4% compound annual growth rate (CAGR), from $83.37M to $87.47M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.